Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®

Published Date:

10/26/12

Series:

HAN ; 331

Language:

English

[PDF-1.09 MB]

Details:

Corporate Authors:

Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; Tennessee.‏ ‎Department of Public Health‏. ;

Description:

October 26, 2012, 18:00 ET (6:00 PM ET)

CDCHAN-00331-2012-26-10-UPD-N

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing.

This HAN notice provides information on the following:

• Status of the investigation

• Background on T T P and Opana ER®

• Recommendations

• Case definition

Subject:

[+]

Document Type:

HAN Health Advisory

Place as Subject:

Tennessee

Collection(s):

Health Alert Network (HAN)

Main Document Checksum:

[+]

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

Thrombotic Thrombocytopenic Purpura (TTP)–Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012

Personal Author:

Marder, Ellyn; Kirschke, David; Robbins, Donna; Dunn, John; Jones, Timothy F.; Racoosin, Judy; Paulozzi, Leonard; Chang, Art;

Published Date:

Jan 11 2013

Source:

MMWR Morb Mortal Wkly Rep. 2013; 62(1):1-4.

Description:

On August 13, 2012, a nephrologist reported to the Tennessee Department of Health (TDH) three cases of unexplained thrombotic thrombocytopenic purpura (TTP), a rare but serious blood disorder characterized by microangiopathic hemolytic anemia and thr...

File Type:

[PDF - 246.34 KB]
MMWR. Morbidity and mortality weekly report, Vol. 62, no. 1, January 11, 2013

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

January 11, 2013

Series:

MMWR. Morbidity and mortality weekly report ; v. 62, no. 1

File Type:

[PDF - 453.00 KB]
Severe Ehrlichia chaffeensis Infection in a Lung Transplant Recipient: A Review of Ehrlichiosis in the Immunocompromised Patient

Personal Author:

Safdar, Nasia; Love, Robert B.; Maki, Dennis G.;

Published Date:

Mar 2002

Source:

Emerg Infect Dis. 8(3):320-323.

Description:

We describe a case of human ehrlichiosis in a lung transplant recipient and review published reports on ehrlichiosis in immunocompromised patients. Despite early therapy with doxycycline, our patient had unusually severe illness with features of thro...

File Type:

[PDF - 172.85 KB]
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)

Personal Author:

Bennett, Charles L.; Jacob, Sony; Dunn, Brianne L.; Georgantopoulos, Peter; Zheng, X Long; Kwaan, Hau C.; McKoy, June M.; Magwood, Jametta S.; Qureshi, Zaina P.; Bandarenko, Nicholas; Winters, Jeffrey L.; Raife, Thomas J.; Carey, Patricia M.; Sarode, Ravindra; Kiss, Joseph E.; Danielson, Constance; Ortel, Thomas L.; Clark, William F.; Ablin, Richard J.; Rock, Gail; Matsumoto, Masanori; Fujimura, Yoshihiro;

Published Date:

Mar 27 2013

Source:

Br J Haematol. 2013; 161(6):896-898.

File Type:

[PDF - 31.98 KB]
MMWR. Morbidity and mortality weekly report, Vol. 35, no. 34, August 29, 1986

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

August 29, 1986

Series:

MMWR. Morbidity and mortality weekly report ; v. 35, no. 34

File Type:

[PDF - 2.31 MB]